Cited by

• Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.

  Harvard S, Guh D, Bansback N, Richette P, Saraux A, Fautrel B, Anis A. Harvard S, et al. Cost Eff Resour Alloc. 2017 Sep 7;15:20. doi: 10.1186/s12962-017-0081-8. eCollection 2017. Cost Eff Resour Alloc. 2017. PMID: 28904528 Free PMC article.
• Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population.

  Lian F, Yang X, Liang L, Xu H, Zhan Z, Qiu Q, Ye Y. Lian F, et al. Rheumatol Int. 2012 Jun;32(6):1663-7. doi: 10.1007/s00296-011-1844-8. Epub 2011 Mar 9. Rheumatol Int. 2012. PMID: 21387110
• Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study.

  Tran-Duy A, Boonen A, van de Laar MA, Severens JL. Tran-Duy A, et al. Cost Eff Resour Alloc. 2015 Oct 7;13:18. doi: 10.1186/s12962-015-0044-x. eCollection 2015. Cost Eff Resour Alloc. 2015. PMID: 26451133 Free PMC article.
• Pulmonary involvement in ankylosing spondylitis.

  Sampaio-Barros PD, Cerqueira EM, Rezende SM, Maeda L, Conde RA, Zanardi VA, Bértolo MB, de Menezes Neto JR, Samara AM. Sampaio-Barros PD, et al. Clin Rheumatol. 2007 Feb;26(2):225-30. doi: 10.1007/s10067-006-0286-2. Epub 2006 Mar 30. Clin Rheumatol. 2007. PMID: 16572281
• Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.

  de Vries HS, van Oijen MG, Driessen RJ, de Jong EM, Creemers MC, Kievit W, de Jong DJ. de Vries HS, et al. Br J Clin Pharmacol. 2011 Jan;71(1):7-19. doi: 10.1111/j.1365-2125.2010.03760.x. Br J Clin Pharmacol. 2011. PMID: 21143496 Free PMC article.